GSK collaborates on immune disease research
GlaxoSmithKline has inked a five year, $25 million collaboration deal with the Disease Institute of Boston to conduct on immunoinflammation research. GSK and IDI researchers will develop joint grant proposals in targeted areas of research under an Alliance Research grant program. GSK gets first dibs on any drug targets identified through the collaboration.
"GSK is committed to becoming a world leader within 3 years in drug discovery of immuno-inflammation," said Jose Carlos Gutierrez-Ramos, head of the Immuno-Inflammation Center of Excellence for Drug Discovery of GSK. "This agreement fits perfectly with our strategy to pursue scientific excellence and technologies both internally and externally."
- see GSK's release for more
Related Articles:
GSK successful in Phase III inflammation trial
GSK shakes up R&D
GSK heralds biotech drug development model


SHARE
WITH: